ArticleJournal of cachexia, sarcopenia and muscle2023
Combined impact of myosteatosis and liver steatosis on prognosis in stage I-III colorectal cancer patients.
Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic impact of myosteatosis on postoperative outcomes and survival in colorectal cancer: a systematic review.International journal of colorectal disease · 2026Pooled it
- Associations of CT-Derived Skeletal Muscle Index and Density With Postoperative Outcomes Following Colorectal Cancer Surgery.Journal of cachexia, sarcopenia and muscle · 2026Article
- Prognostic role of myosteatosis in predicting MACE and mortality after TAVR: insights from CT-based body composition analysis.The journal of nutrition, health & aging · 2026Article
- Article
- The prognostic value of CT-measured body composition combined with radiomics in predicting the survival of patients with resectable colon cancer.La Radiologia medica · 2026Article
- Liver fat and clinical outcomes in individuals with stage I-III colon or rectal cancer.Journal of the National Cancer Institute · 2026Article
- Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances.Current obesity reports · 2025Review
- Novel body component score predicts long-term survival in patients with stage I-III colorectal cancer following radical resection.Annals of gastroenterological surgery · 2025Article
- Combined impact of myosteatosis and liver steatosis on prognosis in stage I-III colorectal cancer patients.Journal of cachexia, sarcopenia and muscle · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMyosteatosis and liver steatosis (LS) have been recognized as patient-derived image biomarkers that correlate with prognosis in colorectal cancer (CRC) patients. However, the significance of considering fat deposition in multiple body areas simultaneously has been underestimated. This study aimed to investigate the combined effect of myosteatosis and LS in stage I-III CRC patients.
methodsA total of 616 stage I-III CRC patients were included in the study. Myosteatosis was assessed using skeletal muscle radiodensity (SMD), and LS was estimated by calculating the Hounsfield unit of the liver and spleen ratio (LSR). Cox proportional hazard models were utilized to evaluate disease-free survival (DFS). A combination of myosteatosis and LS was proposed, and its discriminatory performance was compared using the C-index.
resultsAmong the 616 participants, the median (interquartile) age was 64 (55-72) years, and 240 (38.9%) were female. The median and interquartile range of LSR were determined as 1.106 (0.967-1.225). The optimal cutoff value for LSR was identified as 1.181, leading to the classification of patients into low (410, 66.5%) and high LSR (206, 33.4%) groups. Among the patients, 200 were categorized into the low SMD group, while 416 were allocated to the high SMD group. Both myosteatosis and LS were identified as independent prognostic factors in the multivariable analysis. The combination of these two variables resulted in a three-group classification: high SMD with low LSR group, high SMD with high LSR group, and low SMD group. When comparing the C-index values, the three-group classification exhibited superior discriminatory performance compared with considering myosteatosis and LS separately.
conclusionsMyosteatosis was associated with poorer survival, while the presence of LS was linked to a better prognosis in non-metastatic CRC patients. Simultaneously considering fat infiltration can serve as a more effective prognosticator in non-metastatic CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.